J M Zajecka

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. ncbi Antidepressant dosing and switching guidelines: focus on nefazodone
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 63:42-7. 2002
  2. ncbi Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial
    John Zajecka
    Treatment Research Center, Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychopharmacol 30:135-44. 2010
  3. ncbi Clinical issues in long-term treatment with antidepressants
    J M Zajecka
    Woman s Board Depression Treatment Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 61:20-5. 2000
  4. ncbi Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
    J Clin Psychiatry 63:434-41. 2002
  5. ncbi Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
  6. ncbi Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724-5002, USA
    Biol Psychiatry 54:806-17. 2003
  7. ncbi Six-year perspectives on the safety and tolerability of nefazodone
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, and Center for Anxiety and Depression, Seattle 98105-6099, USA
    J Clin Psychiatry 63:32-41. 2002
  8. ncbi Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
  9. ncbi A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:441-7. 2005
  10. ncbi Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder
    Anita H Clayton
    University of Virginia, Department of Psychiatric Medicine, Charlottesville 22903, USA
    Int Clin Psychopharmacol 18:151-6. 2003

Detail Information

Publications10

  1. ncbi Antidepressant dosing and switching guidelines: focus on nefazodone
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 63:42-7. 2002
    ..In clinical trials, the efficacy of nefazodone was most clearly established at doses between 300 and 600 mg/day. At this dose range, discontinuations because of adverse events are low...
  2. ncbi Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial
    John Zajecka
    Treatment Research Center, Department of Psychiatry, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Psychopharmacol 30:135-44. 2010
    ..The results showed significant antidepressant efficacy of agomelatine 50 mg/d, including a positive effect on sleep compared with placebo in outpatients with moderate to severe major depressive disorder...
  3. ncbi Clinical issues in long-term treatment with antidepressants
    J M Zajecka
    Woman s Board Depression Treatment Research Center, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
    J Clin Psychiatry 61:20-5. 2000
    ....
  4. ncbi Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
    J Clin Psychiatry 63:434-41. 2002
    ..Among patients with a concurrent anxiety disorder, nefazodone. either alone or in combination with CBASP, improves anxiety symptoms faster than CBASP alone, independent of depressive symptom reduction...
  5. ncbi Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
    ..Treatment with nefazodone, CBASP, and combined treatment improved sexual interest/satisfaction, with greatest improvement observed with combined treatment...
  6. ncbi Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724-5002, USA
    Biol Psychiatry 54:806-17. 2003
    ..8%). Somnolence was significantly greater among the patients taking active medication (15.4%), compared with placebo (4.6%). CONCLUSIONS: Nefazodone is well-tolerated and is an effective maintenance therapy for chronic forms of MDD...
  7. ncbi Six-year perspectives on the safety and tolerability of nefazodone
    David L Dunner
    Department of Psychiatry and Behavioral Sciences, University of Washington, and Center for Anxiety and Depression, Seattle 98105-6099, USA
    J Clin Psychiatry 63:32-41. 2002
  8. ncbi Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
    ..Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex...
  9. ncbi A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder
    Maurizio Fava
    Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Psychopharmacol 25:441-7. 2005
    ..This study looks to compare the antidepressant efficacy and safety of a standardized extract of St John's wort with both placebo and fluoxetine...
  10. ncbi Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder
    Anita H Clayton
    University of Virginia, Department of Psychiatric Medicine, Charlottesville 22903, USA
    Int Clin Psychopharmacol 18:151-6. 2003
    ..These results suggest that reboxetine may be of particular benefit for patients at risk for sexual dysfunction with SSRIs...